Germany's Heidelberg Pharma H1 sales revenue surges, driven by milestone payments

Heidelberg Pharma AG

15/07/2026 06:22

Overview
Germany biotech firm’s H1 sales revenue and income rose 84% yr/yr, driven by milestone payments
Operating expenses fell 32% after restructuring, reducing net loss to EUR 3.4 mln from EUR 12.6 mln
Company secured USD 20 mln funding, extending cash reach to mid-2027

Outlook
Heidelberg Pharma confirms 2026 sales revenue and income guidance of EUR 11.0–15.0 mln
Company expects 2026 operating expenses of EUR 25.0–29.0 mln
Heidelberg Pharma aims to complete Phase IIa patient enrollment in Q3 or Q4 2026

Result Drivers
MILESTONE PAYMENTS - Co said higher sales revenue was mainly due to milestone payments from partners Takeda and Huadong and material sales
COST REDUCTIONS - Operating expenses fell 32% yr/yr, attributed to research department reduction and other cost-saving measures
NEW FUNDING - Amended licensing agreement with HealthCare Royalty and Soleus Capital secured USD 20 mln upfront, extending cash reach

Company press release: ID:nEQblzZ2ja

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 EPS
 
-EUR 0.07
 
H1 Net Income
 
-EUR 3.40 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Heidelberg Pharma AG is €5.50, about 111.5% above its July 14 closing price of €2.60

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)